Abstract
Myasthenia gravis (MG) occurs in up to 44% of patients with thymoma. Thirty-three percent of these neoplasms are invasive but extrathoracic disease is rare. Recently, we saw a patient with MG and recurrent, metastasizing mixed lymphoepithelial thymoma, whose disease was resistant to combination chemotherapy and radiotherapy but who responded dramatically to treatment with daily glucocorticoids. Thus, therapy with daily glucocorticoids should be considered in the treatment of invasive or metastatic thymoma associated with MG, including when conventional surgery, radiotherapy, and chemotherapy have failed.
| Original language | English |
|---|---|
| Pages (from-to) | 1286-1290 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 65 |
| Issue number | 6 |
| State | Published - Jan 1 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy. / Tandan, R.; Taylor, R.; DiCostanzo, D. P.; Sharma, Khema R; Fries, T.; Roberts, J.
In: Cancer, Vol. 65, No. 6, 01.01.1990, p. 1286-1290.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metastasizing thymoma and myasthenia gravis. Favorable response to glucocorticoids after failed chemotherapy and radiation therapy
AU - Tandan, R.
AU - Taylor, R.
AU - DiCostanzo, D. P.
AU - Sharma, Khema R
AU - Fries, T.
AU - Roberts, J.
PY - 1990/1/1
Y1 - 1990/1/1
N2 - Myasthenia gravis (MG) occurs in up to 44% of patients with thymoma. Thirty-three percent of these neoplasms are invasive but extrathoracic disease is rare. Recently, we saw a patient with MG and recurrent, metastasizing mixed lymphoepithelial thymoma, whose disease was resistant to combination chemotherapy and radiotherapy but who responded dramatically to treatment with daily glucocorticoids. Thus, therapy with daily glucocorticoids should be considered in the treatment of invasive or metastatic thymoma associated with MG, including when conventional surgery, radiotherapy, and chemotherapy have failed.
AB - Myasthenia gravis (MG) occurs in up to 44% of patients with thymoma. Thirty-three percent of these neoplasms are invasive but extrathoracic disease is rare. Recently, we saw a patient with MG and recurrent, metastasizing mixed lymphoepithelial thymoma, whose disease was resistant to combination chemotherapy and radiotherapy but who responded dramatically to treatment with daily glucocorticoids. Thus, therapy with daily glucocorticoids should be considered in the treatment of invasive or metastatic thymoma associated with MG, including when conventional surgery, radiotherapy, and chemotherapy have failed.
UR - http://www.scopus.com/inward/record.url?scp=0025220493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025220493&partnerID=8YFLogxK
M3 - Article
C2 - 2407333
AN - SCOPUS:0025220493
VL - 65
SP - 1286
EP - 1290
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 6
ER -